跳至主要内容
临床试验/EUCTR2012-005511-11-GB
EUCTR2012-005511-11-GB进行中(未招募)1 期

Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: a prospective double blind randomised control trial - Fibrinogen concentrate to treat postpartum haemorrhage

RACD Cardiff University0 个研究点目标入组 57 人开始时间: 2013年3月15日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
57

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • Inclusion criteria 1) Women Age 18 years or over 2) Women should have any one of the following within the first 12 hours after delivery: a) Haemorrhage of about 1500 mL and ongoing bleeding without another complication or b) Haemorrhage of about 1000 mL and ongoing bleeding with any of: i. caesarean section ii. uterine atony iii. placental abruption iv. placenta praevia v. Cardiovascular instability (arterial blood pressure below 90mm/Hg and heart rate greater than 100 bpm) vi. Clinical observation of microvascular oozing NB. Women can be included if they fulfill the inclusion criteria after delivery of the baby but where the bleeding had started in the antenatal period (antepartum haemorrhage). Women can be included where there is a slow accumulation of on-going blood loss (in the first 12 hours after delivery) if they fulfill the inclusion criteria. Participants will be eligible for randomisation and entry into the interventional phase of the study if there are both • On-going bleeding and • FIBTEM MCF < 18mm
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 1050
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range 0

排除标准

  • Exclusion criteria The following groups will be excluded: 1) Women who have stated that they do not want to participate in the study during the antenatal period 2) Women declining infusion of red blood cells or blood components 3) Known inherited bleeding disorder 4) Placenta accreta diagnosed antenatally 5) Women who have already received uterine brace sutures, uterine tamponade balloons, radiology intervention or hysterectomy before entering the study 6) Clinical suspicion of amniotic fluid embolism 7) Secondary postpartum haemorrhage (haemorrhage which starts >12 hours after delivery)

研究者

发起方
RACD Cardiff University

相似试验

已完成
4 期
Comparison of a single dose fibrinogen with placebo and the number of blood transfusions after ascending aorta surgery (FIBTEG study)
NL-OMON41387Sint Antonius Ziekenhuis82
已完成
不适用
Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: Obstetrics Bleeding Study 2Reproductive Health & ChildbirthPregnancy and ChildbirthPostpartum haemorrhage
ISRCTN46295339Cardiff University (UK)1,050
进行中(未招募)
1 期
se of fibrinogen in the treatment of bleeding in thrombopenic patients after intensive chemotherapy refractory to platelet transfusio- Major patient- Patient with malignant hemopathy requiring intensive chemotherapy, autologous or allogeneic hematopoietic stem cell transplantation- Grade = 1 hemorrhagic symptom according to WHO - WHO classification- Body weight between 38 and 78 kg- Patient presenting with a platelet refractory state defined according to the Corrected Count Increment (CCI)- Patient affiliated to a social security schemeMedDRA version: 21.1Level: LLTClassification code 10066481Term: Hematological malignancySystem Organ Class: 100000004864
EUCTR2021-000990-10-FRInstitut de Cancérologie Lucien Neuwirth10
进行中(未招募)
不适用
REPLACE (Randomized evaluation of fibrinogen versus placeboin complex cardiovascular surgery): a prospective, multinational,multicenter, randomized, double-blind, placebo-controlled, phaseIII study for the use of Fibrinogen Concentrate (Human) (FCH) incomplex cardiovascular surgeryAcute bleeding while undergoing aortic replacement surgeryMedDRA version: 14.1Level: LLTClassification code 10049052Term: Aortic surgery NOSSystem Organ Class: 100000004865
EUCTR2011-002685-20-PLCSL Behring GmbH152
进行中(未招募)
不适用
REPLACE (Randomized evaluation of fibrinogen versus placeboin complex cardiovascular surgery): a prospective, multinational,multicenter, randomized, double-blind, placebo-controlled, phaseIII study for the use of Fibrinogen Concentrate (Human) (FCH) incomplex cardiovascular surgeryAcute bleeding while undergoing aortic replacement surgeryMedDRA version: 14.1Level: LLTClassification code 10049052Term: Aortic surgery NOSSystem Organ Class: 100000004865
EUCTR2011-002685-20-FICSL Behring GmbH152
Fibrinogen concentrate to treat bleeding at the time... | 临床试验